AL01211, a novel oral GCS inhibitor, shows favorable safety and robust biomarker reduction in Phase 2 trial in Fabry patients NEWARK, Calif., August 14, 2025--(BUSINESS WIRE)--AceLink Therapeutics, a ...
SAN FRANCISCO & SHANGHAI--(BUSINESS WIRE)--AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim data ...
NEWARK, Calif.--(BUSINESS WIRE)--AceLink Therapeutics, Inc., a clinical stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs) to address ...
SHANGHAI, Sept. 28, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the ...
Work at Acelink Therapeutics Inc. has led to the identification of Kelch-like ECH-associated protein 1 (Keap1)/Nrf2 interaction inhibitors reported to be useful for the treatment of cancer, lung, ...
(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Autosomal Dominant Polycystic Kidney Disease pipeline constitutes 13+ key companies continuously ...
SHANGHAI, Sept. 28, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results